Tottenham Hotspur Announces Ant International as Global Payment Solutions and Digital Wallet Partner
12.9.2024 15:07:00 CEST | Business Wire | Press release
Club announces strategic partnership with Ant International, a global leader in digital payment and financial technologyThe partnership, which incorporates associated brands Alipay+, WorldFirst and Antom, will see Ant International become the Club’s exclusive Official Global Payment Solutions and Digital Wallet Partner and Alipay+ the first Official Training Wear Sleeve Partner for both the men’s and women’s teamsAnt International will be working with the Club to support growth of and increase engagement with our supporters across the Asia-Pacific region
Tottenham Hotspur has today announced a new three-year strategic partnership with Ant International, a digital payment and financial technology leader.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912483736/en/
Scott Munn (left), Chief Football Officer, Tottenham Hotspur and Yang Peng, Chief Executive Officer, Ant International signed a three-year strategic partnership on Thursday. (Photo: Business Wire)
The partnership sees Ant International, together with its business brands Alipay+, Antom and WorldFirst, become the exclusive Official Global Payment Solutions and Digital Wallet Partner of Tottenham Hotspur, and Alipay+ the first Official Training Wear Sleeve Partner for both the men’s and women’s teams.
The Club will be working with Ant International, through its digital technology solutions brand Alipay+ and merchant payment services brand Antom, to provide a seamless payment experience for fans at our Stadium and on e-commerce platforms, using payment methods widely used in the Asia-Pacific (APAC) region.
Ant International will also support the Club on activations to drive growth of and engagement with our fanbase in the APAC region via its partner digital payment apps, including Alipay. Ant International has a rich portfolio of experience in driving digital engagement through football, having sponsored both the UEFA Euro 2020 and 2024 tournaments.
Yang Peng, Chief Executive Officer, Ant International said: “Football is a game that can be enjoyed by everyone and has the power to transcend borders, bringing people together. This aligns with Ant International’s mission in our globalization – leveraging technological innovation to provide individuals and small businesses with greater access to inclusive financial services.
Tottenham Hotspur has the forward-looking vision of leveraging cutting-edge technologies to enhance fan experience. We resonate with the Club’s ‘To Dare is To Do’ spirit and look forward to working closely with Tottenham Hotspur to engage with its global fanbase through our innovative payment and digitalisation solutions, inspiring the 1.6 billion consumers served by Alipay+ and its partners through the sport and the Club.”
Daniel Levy, Chairman, Tottenham Hotspur said: “The Club and Ant International are fully aligned as we look to deepen connections with our football fans through digital interactions. We shall also be supporting the growth in awareness of the Ant International brand across our extensive global platforms as an elite Premier League Club.
Ant International, together with its ecosystem associates, brings a wealth of experience in digital fan engagement in football following its partnerships during the two most recent UEFA European championships. We are excited to work with them to enhance the digital experience for our fans in-Stadium and online - and further engage our fanbase across the APAC region.”
About Ant International
Headquartered in Singapore, Ant International powers the future of global commerce with digital innovation for everyone and every business to thrive. In close collaboration with partners, we support merchants of all sizes worldwide to realize their growth aspirations through a comprehensive range of tech-driven digital payment and financial services solutions.
About Alipay+
Alipay+ is a suite of cross-border mobile payment and digitalisation technology solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while travelling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
About Antom
Antom is a leading provider of payment and digitisation services to merchants worldwide. Antom provides one-stop, vertical-specific digital payment solutions to meet the payment needs for merchants of all sizes, especially SMEs. With a presence in over 150 markets, Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. Antom also provides digital marketing solutions and merchant digitisation services to help merchant in digital operations and to better engage with their customers.
About WorldFirst
WorldFirst is a one-stop digital payment and financial services platform for global businesses, especially SMEs in international trade. WorldFirst, which employs AI and other cutting-edge technologies for risk control, prioritises the safety and security of client funds above all else and has a leading fraud-prevention track record in the industry. WorldFirst has served one million customers worldwide and is connected to over 120 marketplaces. WorldFirst was founded in 2004 and joined Ant Group in 2019.
About Alipay
In the digital era, Alipay has evolved from a trusted payment tool to an open platform that connects businesses, institutions, service providers, and other partners with consumers. Alipay enables partners from various industries to offer safe and convenient payment options. It also enables partners to communicate and deliver different digital services to their customers in China through Alipay mini programs, lifestyle accounts and other tools. The Alipay platform has connected over 80 million businesses with more than one billion consumers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912483736/en/
Contacts
Media Inquiries
Media Inquiries
Ant International
Fanny Wu
chen.wc@antgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom